STOCK TITAN

[Form 4] Glucotrack, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Glucotrack, Inc. (GCTK) director Erin Catherine Carter reported multiple equity awards and exercises that increased her direct common stock holdings and option position. On 03/25/2025 she was recorded as acquiring 32 shares, followed by 1,000 shares on 07/11/2025 and 386 shares on 10/03/2025, bringing total directly held common stock to 2,148 shares after those transactions. The filing also shows an option grant exercisable beginning 10/03/2025 for 4,055 shares with an exercise price of $7.4 and an expiration in 10/03/2035. The Form 4 notes standard vesting that begins on July 1 of the applicable year and vests monthly over 12 months, and it discloses that reported share figures reflect a series of reverse stock splits implemented in 2024, 02/25/2025, and 06/13/2025.

Il direttore di Glucotrack, Inc. (GCTK), Erin Catherine Carter, ha riportato molteplici premi azionari e esercizi che hanno aumentato le sue partecipazioni dirette di azioni ordinarie e la posizione in opzioni. Il 03/25/2025 è stata registrata come l'acquisizione di 32 azioni, seguita da 1,000 azioni il 07/11/2025 e 386 azioni il 10/03/2025, portando le azioni ordinarie detenute direttamente a 2,148 azioni dopo tali transazioni. La dichiarazione mostra anche una concessione di opzioni esercitabili a partire dal 10/03/2025 per 4,055 azioni con prezzo di esercizio di $7.4 e una scadenza nel 10/03/2035. Il Form 4 annota un vesting standard che inizia il 1 luglio dell'anno applicabile e matura mensilmente nell'arco di 12 mesi, e rivela che le cifre riportate riflettono una serie di reverse stock splits implementati nel 2024, 02/25/2025 e 06/13/2025.
El director de Glucotrack, Inc. (GCTK), Erin Catherine Carter, reportó múltiples premios de acciones y ejercicios que aumentaron sus participaciones directas de acciones ordinarias y su posición en opciones. El 03/25/2025 se registró como la adquisición de 32 acciones, seguido de 1,000 acciones el 07/11/2025 y 386 acciones el 10/03/2025, llevando el total de acciones comunes directamente poseídas a 2,148 acciones después de esas transacciones. El expediente también muestra una concesión de opciones ejercitable a partir del 10/03/2025 para 4,055 acciones con un precio de ejercicio de $7.4 y una expiración en 10/03/2035. El Form 4 señala un vesting estándar que comienza el 1 de julio del año aplicable y que vence mensualmente durante 12 meses, y divulga que las cifras de acciones reportadas reflejan una serie de split inversos de acciones implementados en 2024, 02/25/2025 y 06/13/2025.
Glucotrack, Inc. (GCTK) 이사인 Erin Catherine Carter는 직접 보통주 보유 및 옵션 포지션을 증가시킨 다수의 주식 보상 및 행사 를 보고했습니다. 03/25/2025에 그녀는 32주를 취득한 것으로 기록되었고, 이어 07/11/20251,000주, 10/03/2025386주가 더해져 그 거래들 후에 직접 보유 보통주 총수가 2,148주에 이르게 되었습니다. 제출서류에는 또한 10/03/2025부터 행사 가능한 4,055주에 대한 행사가 $7.4의 행사 가격과 10/03/2035의 만기가 있는 옵션 부여가 표시됩니다. Form 4는 연도 해당 연도 7월 1일에 시작되어 12개월 동안 매월 vesting되는 표준 vesting을 기록하고, 보고된 주식 수치는 2024년, 2025년 2월 25일, 2025년 6월 13일에 실행된 일련의 역분할(reverse stock splits)을 반영한다는 것을 공개합니다.
Le directeur de Glucotrack, Inc. (GCTK), Erin Catherine Carter, a rapporté plusieurs rémunérations en actions et exercices qui ont augmenté ses avoirs directs d'actions ordinaires et sa position en options. Le 03/25/2025 a été enregistré comme l'acquisition de 32 actions, suivie de 1,000 actions le 07/11/2025 et 386 actions le 10/03/2025, portant le total des actions ordinaires détenues directement à 2,148 actions après ces transactions. Le dépôt montre également une attribution d'options exerçables à partir du 10/03/2025 pour 4,055 actions avec un prix d'exercice de $7.4 et une expiration le 10/03/2035. Le Form 4 indique une vesting standard qui commence le 1er juillet de l'année applicable et vest mensuellement sur 12 mois, et il révèle que les chiffres d'actions déclarés reflètent une série de divisions d'actions inverses mises en œuvre en 2024, 02/25/2025, et 06/13/2025.
Der Direktor von Glucotrack, Inc. (GCTK), Erin Catherine Carter, meldete mehrere Aktienzuteilungen und Übungen, die ihre direkten Stammaktienbestände und Optionenposition erhöhten. Am 03/25/2025 wurde sie als Erwerberin von 32 Aktien verzeichnet, gefolgt von 1,000 Aktien am 07/11/2025 und 386 Aktien am 10/03/2025, wodurch sich die direkt gehaltenen Stammaktien nach diesen Transaktionen auf insgesamt 2,148 Aktien erhöhten. Die Einreichung zeigt außerdem eine Optionszuteilung, die ab dem 10/03/2025 ausübbar ist, für 4,055 Aktien mit einem Ausübungspreis von $7.4 und einer Laufzeit bis zum 10/03/2035. Das Form 4 vermerkt eine Standard-Vesting, die am 1. Juli des jeweiligen Jahres beginnt und über 12 Monate monatlich vestet, und es wird offengelegt, dass die berichteten Aktienzahlen eine Serie von Reverse Stock Splits widerspiegeln, die im 2024, 02/25/2025 und 06/13/2025 umgesetzt wurden.
أعلنت مديرة Glucotrack, Inc. (GCTK)، إيرين كاثرين كارتر عن منح أسهم متعددة وممارسات تمكّنت من زيادة حصّتها المباشرة من الأسهم العادية ومركزها في الخيارات. في 03/25/2025 سُجلت كإضافة 32 سهمًا، تلتها 1,000 سهم في 07/11/2025 و386 سهمًا في 10/03/2025، مما رفع إجمالي الأسهم العادية المملوكة مباشرة إلى 2,148 سهمًا بعد تلك المعاملات. كما يظهر الملف منح خيار قابل للتفعيل ابتداءً من 10/03/2025 لـ 4,055 سهمًا بسعر تنفيذ قدره $7.4 ونهاية صلاحيته في 10/03/2035. يشير النموذج Form 4 إلى vesting قياسي يبدأ في الأول من يوليو من السنة المعنية ويتقاسم شهريًا خلال 12 شهرًا، كما يكشف أن أعداد الأسهم المبلغ عنها تعكس سلسلة تقسيمات عكسية للأسهم نفذت في 2024 و02/25/2025 و06/13/2025.
Glucotrack, Inc. (GCTK) 董事 Erin Catherine Carter 报告了多项股票奖励与行权,增加了她的直接普通股持有量和期权头寸。于 03/25/2025 记录她获得了 32 股,随后在 07/11/2025 增加了 1,000 股,在 10/03/2025 再增 386 股,使直接持有的普通股总数在这些交易后达到 2,148 股。 文件还显示自 10/03/2025 起可行使的 4,055 股期权,行使价为 $7.4,到期日为 10/03/2035。Form 4 指出标准的归属在相关年度的 7 月 1 日开始,并在 12 个月内按月归属,且披露报告的股数反映了在 202402/25/202506/13/2025 实施的一系列股票回购/反向拆分。
Positive
  • Director increased direct ownership to 2,148 shares, signaling continued insider participation
  • Option grant of 4,055 shares provides long‑dated alignment through 10/03/2035
Negative
  • Exercise price of $7.4 may be above recent market levels (market level not provided in filing)
  • Vesting tied to continued service, so shares/options are subject to forfeiture if service ends before vesting

Insights

Director received scheduled equity awards and increased direct ownership.

The transactions show a director-level recipient acquiring 2,148 common shares through three non‑derivative acquisitions across 03/25/2025 to 10/03/2025

These moves follow standard equity grant mechanics with a stated monthly vesting schedule commencing on July 1; the board-level status is relevant because director holdings affect alignment with shareholders and governance optics over the next 12 months.

A stock option for 4,055 shares at $7.4 vests monthly and expires on 10/03/2035.

The option's exercise price and ten‑year term are explicitly stated and the filing ties vesting to continued service, with monthly vesting over a 12‑month period after the July 1 start.

Because the filing reflects multiple reverse stock splits, the share counts are adjusted; investors tracking dilution should compare post‑split figures to outstanding share totals on the same post‑split basis within the same timeframe.

Il direttore di Glucotrack, Inc. (GCTK), Erin Catherine Carter, ha riportato molteplici premi azionari e esercizi che hanno aumentato le sue partecipazioni dirette di azioni ordinarie e la posizione in opzioni. Il 03/25/2025 è stata registrata come l'acquisizione di 32 azioni, seguita da 1,000 azioni il 07/11/2025 e 386 azioni il 10/03/2025, portando le azioni ordinarie detenute direttamente a 2,148 azioni dopo tali transazioni. La dichiarazione mostra anche una concessione di opzioni esercitabili a partire dal 10/03/2025 per 4,055 azioni con prezzo di esercizio di $7.4 e una scadenza nel 10/03/2035. Il Form 4 annota un vesting standard che inizia il 1 luglio dell'anno applicabile e matura mensilmente nell'arco di 12 mesi, e rivela che le cifre riportate riflettono una serie di reverse stock splits implementati nel 2024, 02/25/2025 e 06/13/2025.
El director de Glucotrack, Inc. (GCTK), Erin Catherine Carter, reportó múltiples premios de acciones y ejercicios que aumentaron sus participaciones directas de acciones ordinarias y su posición en opciones. El 03/25/2025 se registró como la adquisición de 32 acciones, seguido de 1,000 acciones el 07/11/2025 y 386 acciones el 10/03/2025, llevando el total de acciones comunes directamente poseídas a 2,148 acciones después de esas transacciones. El expediente también muestra una concesión de opciones ejercitable a partir del 10/03/2025 para 4,055 acciones con un precio de ejercicio de $7.4 y una expiración en 10/03/2035. El Form 4 señala un vesting estándar que comienza el 1 de julio del año aplicable y que vence mensualmente durante 12 meses, y divulga que las cifras de acciones reportadas reflejan una serie de split inversos de acciones implementados en 2024, 02/25/2025 y 06/13/2025.
Glucotrack, Inc. (GCTK) 이사인 Erin Catherine Carter는 직접 보통주 보유 및 옵션 포지션을 증가시킨 다수의 주식 보상 및 행사 를 보고했습니다. 03/25/2025에 그녀는 32주를 취득한 것으로 기록되었고, 이어 07/11/20251,000주, 10/03/2025386주가 더해져 그 거래들 후에 직접 보유 보통주 총수가 2,148주에 이르게 되었습니다. 제출서류에는 또한 10/03/2025부터 행사 가능한 4,055주에 대한 행사가 $7.4의 행사 가격과 10/03/2035의 만기가 있는 옵션 부여가 표시됩니다. Form 4는 연도 해당 연도 7월 1일에 시작되어 12개월 동안 매월 vesting되는 표준 vesting을 기록하고, 보고된 주식 수치는 2024년, 2025년 2월 25일, 2025년 6월 13일에 실행된 일련의 역분할(reverse stock splits)을 반영한다는 것을 공개합니다.
Le directeur de Glucotrack, Inc. (GCTK), Erin Catherine Carter, a rapporté plusieurs rémunérations en actions et exercices qui ont augmenté ses avoirs directs d'actions ordinaires et sa position en options. Le 03/25/2025 a été enregistré comme l'acquisition de 32 actions, suivie de 1,000 actions le 07/11/2025 et 386 actions le 10/03/2025, portant le total des actions ordinaires détenues directement à 2,148 actions après ces transactions. Le dépôt montre également une attribution d'options exerçables à partir du 10/03/2025 pour 4,055 actions avec un prix d'exercice de $7.4 et une expiration le 10/03/2035. Le Form 4 indique une vesting standard qui commence le 1er juillet de l'année applicable et vest mensuellement sur 12 mois, et il révèle que les chiffres d'actions déclarés reflètent une série de divisions d'actions inverses mises en œuvre en 2024, 02/25/2025, et 06/13/2025.
Der Direktor von Glucotrack, Inc. (GCTK), Erin Catherine Carter, meldete mehrere Aktienzuteilungen und Übungen, die ihre direkten Stammaktienbestände und Optionenposition erhöhten. Am 03/25/2025 wurde sie als Erwerberin von 32 Aktien verzeichnet, gefolgt von 1,000 Aktien am 07/11/2025 und 386 Aktien am 10/03/2025, wodurch sich die direkt gehaltenen Stammaktien nach diesen Transaktionen auf insgesamt 2,148 Aktien erhöhten. Die Einreichung zeigt außerdem eine Optionszuteilung, die ab dem 10/03/2025 ausübbar ist, für 4,055 Aktien mit einem Ausübungspreis von $7.4 und einer Laufzeit bis zum 10/03/2035. Das Form 4 vermerkt eine Standard-Vesting, die am 1. Juli des jeweiligen Jahres beginnt und über 12 Monate monatlich vestet, und es wird offengelegt, dass die berichteten Aktienzahlen eine Serie von Reverse Stock Splits widerspiegeln, die im 2024, 02/25/2025 und 06/13/2025 umgesetzt wurden.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carter Erin Catherine

(Last) (First) (Middle)
C/O GLUCOTRACK, INC.
301 RTE 17 NORTH, STE. 800

(Street)
RUTHERFORD NJ 07070

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Glucotrack, Inc. [ GCTK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 per share 03/25/2025 A 32 A $0 762 D
Common Stock, par value $0.001 per share 07/11/2025 A 1,000 A $0 1,762 D
Common Stock, par value $0.001 per share 10/03/2025 A 386 A $0 2,148 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $7.4 10/03/2025 A 4,055 (1) 10/03/2035 Common Stock, par value $0.001 per share 4,055 $0 4,055 D
Explanation of Responses:
1. Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.
Remarks:
On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's common stock, par value $0.001 per share (the "Common Stock") was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "February 2025 Reverse Split"), and on June 13, 2025, a 1-for-60 reverse stock split of the Common Stock was implemented (the "June 2025 Reverse Stock Split", and together with the 2024 Reverse Split and the February 2025 Reverse Stock Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 10/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Erin Catherine Carter report on Form 4 for GCTK?

The filing reports acquisitions of 32 shares on 03/25/2025, 1,000 shares on 07/11/2025, and 386 shares on 10/03/2025, plus a stock option for 4,055 shares exercisable from 10/03/2025 at $7.4.

How many total common shares does the director hold after these transactions?

The director's reported beneficial ownership following the listed non‑derivative transactions is 2,148 shares.

What are the key terms of the option reported in the Form 4 for GCTK?

The option covers 4,055 underlying shares, has an exercise price of $7.4, becomes exercisable on 10/03/2025, and expires on 10/03/2035.

Do the reported share counts reflect any corporate actions?

Yes; the Form 4 states that all figures reflect reverse stock splits on May 17, 2024, 02/25/2025, and 06/13/2025.

What is the vesting schedule for the reported option grants?

Each option grant has a vesting commencement date of July 1 of the applicable year and vests in 12 equal monthly installments over the following 12 months, subject to continued service.
Glucotrack

NASDAQ:GCTK

GCTK Rankings

GCTK Latest News

GCTK Latest SEC Filings

GCTK Stock Data

7.28M
849.51k
5.55%
0.81%
4.51%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
RUTHERFORD